- Home
- HALO vs ABVX Comparison
HALO vs ABVX Comparison
Compare HALO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HALO
- ABVX
- Stock Information
- Founded
- HALO 1998
- ABVX 2013
- Country
- HALO United States
- ABVX France
- Employees
- HALO N/A
- ABVX N/A
- Industry
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- ABVX
- Sector
- HALO Health Care
- ABVX
- Exchange
- HALO Nasdaq
- ABVX Nasdaq
- Market Cap
- HALO 7.6B
- ABVX 6.7B
- IPO Year
- HALO N/A
- ABVX N/A
- Fundamental
- Price
- HALO $66.96
- ABVX $92.67
- Analyst Decision
- HALO Buy
- ABVX Strong Buy
- Analyst Count
- HALO 11
- ABVX 10
- Target Price
- HALO $73.09
- ABVX $103.80
- AVG Volume (30 Days)
- HALO 2.2M
- ABVX 1.1M
- Earning Date
- HALO 11-04-2025
- ABVX 08-11-2025
- Dividend Yield
- HALO N/A
- ABVX N/A
- EPS Growth
- HALO 68.93
- ABVX N/A
- EPS
- HALO 4.37
- ABVX N/A
- Revenue
- HALO $1,178,672,000.00
- ABVX $7,073,400.00
- Revenue This Year
- HALO $32.57
- ABVX $4.44
- Revenue Next Year
- HALO $23.77
- ABVX N/A
- P/E Ratio
- HALO $15.35
- ABVX N/A
- Revenue Growth
- HALO 34.97
- ABVX N/A
- 52 Week Low
- HALO $42.01
- ABVX $4.77
- 52 Week High
- HALO $79.50
- ABVX $98.64
- Technical
- Relative Strength Index (RSI)
- HALO 41.47
- ABVX 65.30
- Support Level
- HALO $63.80
- ABVX $85.00
- Resistance Level
- HALO $68.00
- ABVX $98.59
- Average True Range (ATR)
- HALO 2.30
- ABVX 3.87
- MACD
- HALO -0.48
- ABVX 0.09
- Stochastic Oscillator
- HALO 25.24
- ABVX 64.53
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.